Key Highlights

  • Evolent Health (NYSE:EVH) traded 5.47% lower at USD 3.71 in intraday data on Thursday, November 19, 2026, a price well below USD 5 and therefore a low-priced stock.
  • Revenue climbed to USD 725.4 million from USD 479.5 million, while adjusted EBITDA contracted to USD 34.3 million, versus USD 39.0 million a year before.
  • Medical expense ratio moved up to 93.0% from 85.0%, and the adjusted EBITDA Margin compressed from 8.1% to 4.7% over the same comparison.
  • The 2026 adjusted EBITDA outlook was lifted to USD 130.0 million to USD 135.0 million, and Revenue expectations stayed in a band of USD 2.6 billion to USD 2.7 billion.

Decline Arrives Without a Fresh Company Announcement

Evolent Health (NYSE:EVH) fell 5.47%, close to 5.5%, to USD 3.71 on Thursday, November 19, 2026, based on intraday data. Searches for November 17 to 19 found no company announcement explaining the drop, and the most recent confirmed event is the third-quarter release from November 5, 2026. The firm is a specialty care management provider based in Washington, D.C., offering cancer and cardiology programs to health plans and provider groups. A decline of this scale in a stock under USD 5 is not in itself news, so the fundamentals below are a better guide than any single headline. No analyst action or filing in the verified window ties to the shares, and reaction pieces on earlier Evolent selloffs date from 2025 and are not relied upon here.

Revenue Growth Runs Into a Higher Medical Expense Ratio

For the three months ended September 30, 2026, Evolent generated USD 725.4 million of revenue, up from USD 479.5 million. The loss attributable to common shareholders was USD 23.6 million, or USD 0.21 per share, against USD 26.9 million, or USD 0.24, a year before. On an adjusted basis common holders earned USD 7.3 million, which equals USD 0.06 a share. The medical expense ratio, the slice of sales turned into medical costs under risk-based deals, climbed to 93.0% from 85.0%, which pushed adjusted EBITDA down to 4.7% of revenue. Over nine months, sales came to USD 1,874.1 million, with a net loss of USD 78.6 million. Nine-month sales equal about 72% of the USD 2.6 billion lower bound of full-year guidance, which implies a Q4 of at least around USD 726 million (both calculated).

Leverage, Debt Paydown and Contract Renewals Set the Risk

At September 30, 2026, cash and equivalents of USD 148.3 million compared with net long-term debt of USD 969.5 million, leaving about USD 821.2 million of debt after netting cash (calculated). Management plans to put up to USD 50 million toward reducing indebtedness by year-end. On the contract side, the company re-signed its biggest Surgical Management agreement for a four-year term, widened oncology coverage for an existing client that spans roughly 1 million commercial lives starting January 1, 2027, and stretched a national payer tie-up into 11 further states. Margin squeeze, Leverage and medical cost trajectories are the core hazards, and seven renewals and new revenue agreements this year will need time to feed through to margins.

Where Things Stand

Evolent Health (NYSE:EVH) is trading 5.47% lower with no company announcement tied to the move, so no single event should be credited. The most recent verified picture is a blend: sales jumped and the adjusted EBITDA outlook moved higher, yet the medical expense ratio hit 93.0% and debt sits heavy against cash. Upcoming checkpoints include the year-end debt paydown, the oncology start on January 1, 2027 and the fourth-quarter report. The company has made no comment on today's trading.